Capricor Therapeutics, Inc. , a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has signed definitive agreements for the sale of approximately $7.0 million of the Company's common stock to select investors at a price of $4.25 per share. The closing of the offering is expected to take place on or about February 9, 2015, subject to the satisfaction of customary closing conditions.
http://ift.tt/1KryAaG
http://ift.tt/1KryAaG
No comments:
Post a Comment